Shanghai Henlius Biologics Co., Ltd.

HONG KONG, Jan. 2, 2024 /PRNewswire/ -- In the blink of an eye, 2023 is coming to an end. Thank you for your hard work and dedication. It has been a year of relentless efforts toward hope. After experiencing the three-year epidemic, many families have made plans for the new year from the beginning of the year and are eager to travel with their family. This year's tourism rebound has been particularly pronounced. Club Med and Atlantis Sanya under Fosun Tourism Group achieved their best performance over the same period. The business volume of Atlantis Sanya in the first three quarters of 2023 exceeded RMB1.3 billion, representing an increase of approximately 83.2% compared with the same period in 2022, becoming the key engine for the recovery of Sanya's cultural tourism economy. Capitalizing on this momentum, we opened two Club Med Urban Oasis resorts in Nanjing, China and Taicang, China at the end of the year to create urban vacation experience. In particular, Alps Snow Live in Taicang has gained widespread attention and popularity since its opening and became an internet-famous. No matter how the world changes, Fosun always believes that people's pursuit of a brighter life remains unchanged, and we will keep pushing towards this direction. The past twelve months have been extremely fulfilling for me. I travelled to many countries and took a closer look at many projects. There were farewells and harvests. There is a kind of love called letting go. Fosun has invested in Nanjing Iron & Steel since 2003. Although was a difficult decision, we officially completed the disposal of Nanjing Nangang at the end of 2023, which further steeled Fosun's determination to focus on core businesses in the household consumption sector. After twenty years of working together, and with the efforts of all Nanjing Iron & Steel staff, Nanjing Iron & Steel has become a very competitive modern steel company in China's steel industry. Despite the overall industry downturn this year, it still registered a monthly profit of about RMB300 million, which was not easy, and I would like to congratulate them again; On the other hand, Club Med Kiroro Grand in Hokkaido, Japan officially opened, and I took my family there for a ski trip. The launch implies that Club Med has further established its leading brand and dominant position in the skiing industry in Hokkaido and even the world; Fosun has once again made a lot of great achievements in the field of health in 2023, including the domestic production of da Vinci robotic surgical system and the record-breaking sales of HANQUYOU. At the beginning of the year, Shanghai Henlius's self-developed HANSIZHUANG was approved for its third indication, becoming the world's first anti-PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer, offering a new treatment option for patients with small cell lung cancer and setting a new benchmark for domestic tumor immunotherapy. At the end of the year, we were also very pleased to see that Fosun Pharma and Shenzhen officially reached a cooperation agreement on the RMB5.0 billion fund for innovative drug development. As an innovative company rooted in Shanghai, we also look forward to working and collaborating with more cities; And, Wolverhampton Wanderers F.C. ("Wolves") snapped a three-game winning streak during the busy month of December. The year 2023 has brought us many surprises, and also gave us more to look forward in 2024. With the gradual easing of Sino-US relations, we believe that the two countries must compete and cooperate. The "coopetition" (coopetitive relationship) between China and the United States also brings benefits to the global market. Since the U.S. Federal Reserve meeting in September this year, the U.S. Federal Reserve has suspended interest rate hikes for three consecutive meetings, which seems to indicate the end of rate hikes and signal rate cuts in 2024. The overall economy will then be stimulated, injecting vitality to capital markets globally, including China. Although the offline retail market has not fully recovered in 2023, people's pursuit for a brighter life will definitely drive the market to further release more vitality in the new year. After experiencing the past thirty years, Fosun will continue its focused strategy in the future. Fosun used to explore different sectors and develop businesses in parallel in its exploratory stage. Now we have explored many sectors and found industries in which we can form advantages. In the future, we will combine our own characteristics, focus on these industries and further develop high value-added businesses. Looking ahead, I hope Fosun will become an organization that brings warmth to the world. This year, I am also very delighted that our Yuyuan Garden Lantern Festival made its overseas debut. Starting from 15 December, the Festival Dragons et Lanternes has officially opened to the public at the Jardin d'Acclimatation in Paris, France. Meanwhile, 9,300 kilometers away from the Jardin d'Acclimatation, Yuyuan Garden in Shanghai is ablaze with the Ninghui Road-themed lantern installation "A Night of Fish and Dragon Dance", sending New Year's greetings to families worldwide and celebrating the Year of the Dragon with all. Finally, I would like to thank Fosuners for your hard work and dedication. The New Year has arrived. I hope everyone will find hobbies to enjoy, take good care of their health, and continue to work diligently for the health, happiness, and wealth of one billion families worldwide. Believe in yourself and the future in 2024. Happy New Year! SOURCE Fosun

SHANGHAI, CHINA and TAIPEI, TAIWAN / ACCESSWIRE / August 28, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines, and Shanghai Henlius Biotech, Inc., a global biopharmaceutical company developing biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases, today announced that the two companies have entered into a strategic framework agreement for collaboration to combine HanchorBio's protein engineering expertise and proprietary Fc-based designer biologics (FBDB™) technology platform with Henlius' integrated product development and commercialization capabilities. The collaboration aims to expand the application of each company's platform by developing novel cancer immunotherapies, including those tumors resistant to anti-PD-1/L1 immunotherapies, to accelerate their respective pipeline of innovative immunotherapy medicines. "FBDB™-based innovative products may offer effective cancer immunotherapies to patients suffering from cancers which are resistant or refractory to PD-1/PD-L1 blockade therapies and having significant unmet medical needs on a global scale," said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. "This collaboration represents a foundational recognition and investment in our platform science and capabilities, which strengthens our pipeline and accelerates our research to providing novel therapies to patients globally. We are thrilled to collaborate with Shanghai Henlius to jointly address the inadequacies of the current anti-PD-1/L1 therapies and to navigate new frontiers in immuno-oncology through the design and development of novel multi-functional modalities that synergistically modulate and re-engage immune systems to fight cancers." Mr. Jason Zhu, Chief Executive Officer, President, and Chief Financial Officer of Henlius, said, "Henlius is dedicated to providing affordable and innovative biologics for patients around the world. Today, we have achieved great success in marketing 5 products to the global market. Focusing on unmet clinical needs, Henlius actively collaborates with our global leading partners to pursue discovery and technology advance. HanchorBio was founded by Dr. Scott Liu, one of the co-founders of Henlius, and the Company possesses an experienced management team with a great mission and vision. Taking innovation as a driver, HanchorBio has quickly built its differentiated advantages and stands out in the field of onco-immunotherapy. This collaboration will allow Henlius to further accelerate our practice of affordable innovation and benefit more patients worldwide by fully leveraging HanchorBio's leading-edge technology and R&D platform." About the Collaboration With this collaboration, Henlius will consider early licensing and/or establish research collaboration of promising products from HanchorBio's pipeline that are complementary to Henlius' current portfolio (e.g., FBDBTM platform molecules, engineered immunocytokines etc.). This will be detailed in a separate agreement upon successful presentation of relevant efficacy/safety data. Under the terms of the agreement, Henlius will also have the opportunity to opt-in and co-develop the selected products with HanchorBio. About Henlius Henlius is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing, and commercialization. It has established global innovation centers and Shanghai-based manufacturing facilities in compliance with global Good Manufacturing Practice (GMP), including Xuhui Plant certificated by China and the EU GMP and Songjiang-I Plant certificated by China GMP. Apart from the launched biosimilar products HANLIKANG (rituximab), HANQUYOU (trastuzumab) for injection, trade name in Europe: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG (anti-PD-1) has been approved by the NMPA for the treatment of MSI-H solid tumors, squamous non-small cell lung cancer (sqNSCLC), and extensive-stage small cell lung cancer (ES-SCLC), making it the world's first anti-PD-1 monoclonal antibody for the first-line treatment of SCLC. Its NDA for the treatment of esophageal squamous cell carcinoma (ESCC) is under review. What's more, Henlius has conducted over 30 clinical trials for 16 products, expanding its presence in major and emerging markets. About HanchorBio Based in Taipei, Shanghai, and San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with proven track-record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs. For more information, please visit: or follow us on LinkedIn at Contact Information Scott Liu Founder, Chairman and CEO scott_liu@hanchorbio.com Yi Du Sr. Director of Business Development yi_du@hanchorbio.com SOURCE: HanchorBio Inc. View source version on accesswire.com:

HONG KONG, June 8, 2023 /PRNewswire/ -- On 8 June 2023, the 2023 Fosun International Investor Open Day was held in Shanghai. It was the first time that Fosun International had held a large-scale offline open day after the pandemic. More than 100 domestic and foreign investor representatives from BlackRock, J.P. Morgan Securities, UBS SDIC, Taiping Asset Management, CICC, GF Securities and other institutions participated in the event. The investor relations team of Fosun International gave investors an in-depth tour of Fosun Pharma headquarters, the Grand Yuyuan, the Bund Finance Center (BFC), etc. to learn more about the development of Fosun International's pharmaceutical, culture and tourism, consumer, medical aesthetics and other industries. After winning out over the "perfect storm" in 2022, Fosun has been maintaining its strategic focus and accelerating the implementation of the business streamlining and core business-focused strategy. It has been widely recognized by investors for its sustained and sound financial performance, continuous consolidation of industry operations driven by innovation, and robust development momentum of its core businesses in the household consumption sector to build resilience. At the investor open day, management of Fosun International and its listed subsidiaries including Fosun Pharma, Shanghai Henlius, Fosun Tourism Group (FTG), Yuyuan Inc., Shede Spirits, Lanvin Group, Sisram Med, and Hainan Mining conducted face-to-face and in-depth exchanges with investors. Fosun successfully won out over the "perfect storm" and affirmed by the capital market In 2022, in the face of the complex and ever-changing external environment, Fosun successfully won out over the "perfect storm" and demonstrated strong strategic determination and execution capability in implementing its business streamlining strategy. Entering 2023, the results of this strategy are gradually emerging. Alex Gong, Executive Director, Executive President, and Chief Financial Officer of Fosun International, shared that Fosun has adopted multiple measures to continuously optimize funds and capital structure and deleverage, thus the Group's liquidity pressure has been greatly eased. For the full year of 2022, the amount by contract value based on consideration set out in the divestment agreements exceeded RMB40.0 billion, bringing a cash inflow of nearly RMB30.0 billion at holding company level. As of the end of March 2023, Fosun successfully brought down holding-company debt by about RMB24.0 billion to RMB93.0 billion. At the same time, Fosun has been actively expanding its financing channels to further consolidate capital buffer. In January this year, Fosun obtained a syndicated loan of RMB12.0 billion which was formed by five major state-owned commercial banks including Industrial and Commercial Bank of China, Agricultural Bank of China, Bank of China, China Construction Bank, and Bank of Communications as joint lead banks; in early May this year, Fosun's offshore multi-currency syndicated loan was officially launched, and it has obtained a loan of more than US$450 million in equivalent so far. Investors who participated in the open day noticed that on 30 May, international rating agency S&P Global Ratings issued a report, raising the rating outlook of Fosun International to stable. S&P Global Ratings pointed out that Fosun secured sufficient sources of liquidity amid turbulence in the bond market, and successfully repaid all concentrated maturing bonds in the past three quarters. Moreover, Fosun's proportion of debts due over the next 12 months dropped significantly, and the stability of the debts improved significantly. Chu Min, Chief Analyst of Social Services at Kaiyuan Securities, said: "Driven by strong strategic determination, Fosun International's fundamentals continue to improve, and its mid-to-long-term development has sufficient resilience and flexibility. Through face-to-face communication and on-site visit on the open day, we believe that Fosun's core business-focused strategy particularly in the household consumption sector with high growth potential, together with the Group's capability to leverage its global assets to graft global resources for global customers, will enable Fosun to achieve more valuable growth." Innovation-driven strategy to lead the way with "world's first" and "China's first" Innovation has always been the "core engine" that drives the development of Fosun. In 2022, Fosun's R&D investment reached RMB10.4 billion, representing a year-on-year increase of 17%. Its long-term R&D investment has also continued to reap results. At the event, persons in charge of Fosun Pharma and Shanghai Henlius introduced the latest progress of multiple "world's first" and "China's first" products in the Health segment under the empowerment of global operations. Since its launch in March 2022, Shanghai Henlius' self-developed HANSIZHUANG (serplulimab injection) has been approved for three indications in China, and has become the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer. It had generated a revenue of more than RMB300 million within nine months of its launch. In the first quarter of this year, HANSIZHUANG achieved a revenue of RMB249.8 million in the domestic market, among which the monthly revenue exceeded RMB100 million for the first time in March, marking that this innovative drug has entered a new stage of sales growth, and the commercialization of this product has gained robust momentum. In addition, the United States (U.S.) biologics license application (BLA) of HANQUYOU (trastuzumab injection), the first domestic monoclonal antibody biosimilar approved in both China and the European Union (EU), has been accepted by the U.S. Food and Drug Administration (FDA), which is expected to become the first domestic monoclonal antibody biosimilar approved in China, the EU and the U.S., further covering the mainstream biopharmaceutical markets in Europe and the U.S. The development of new and sub-new products has also promoted the steady growth of Fosun Pharma's revenue and profit. In the first quarter of this year, Fosun Pharma achieved an operating revenue of RMB10.871 billion, representing a year-on-year increase of 4.68%; net profit attributable to shareholders of the listed company after deducting extraordinary gain and loss was RMB919 million, representing a year-on-year increase of 14.78%. The general upward trend leads to a strong recovery in the household consumption businesses The recovery of domestic consumption and the relaxation of travel restrictions worldwide have led to a strong recovery in Fosun's businesses in the consumer and tourism sectors. At the open day event, investors took a tour of the Grand Yuyuan from Yuyuan Tourist Mart to the BFC and visited Fosun's time-honored brands such as Tong Han Chun Tang, Laomiao, and Songhelou, international brands such as Lanvin, and Sergio Rossi, and learnt more about Sisram Med's medical aesthetics and personal care products in Joyful Way, truly experiencing market vitality boosted by consumption recovery. The performance of the listed companies in Fosun's Happiness segment also exemplifies investors' research sentiment. In the first quarter of this year, Yuyuan achieved an operating revenue of RMB15.244 billion, representing a year-on-year increase of 22.61%; among them, the revenue of Yuyuan Jewelry and Fashion reached RMB11.494 billion, representing a year-on-year increase of 28.55%; both the customer traffic and business volume of Yuyuan Tourist Mart have achieved good results, with customer traffic rising 87% compared with the same period in 2022; the revenue and net profit of Shede Spirits have both increased, and the proportion of mid-to-high-end spirits sales has continued to rise. Fosun's tourism business saw even stronger business rebound. In the first quarter of this year, FTG's net profit attributable to the parent doubled compared with the same period in 2022, of which, Club Med's business volume reached RMB5.004 billion, an increase of about 44.2% compared with the same period in 2022. During the May Day holiday this year, the total business volume of Atlantis Sanya exceeded five times that of the same period in 2022, and the total number of visitors reached 115,000. As the first U.S.-listed company under Fosun, Lanvin Group recently released its first annual report since its listing at the end of 2022. According to the data, five major brands of Lanvin Group, including Lanvin and Sergio Rossi, all achieved year-on-year growth, with annual revenue rising 37% year-on-year to EUR422 million, maintaining industry-leading growth in the global luxury goods industry. Alex Gong, Executive Director, Executive President, and Chief Financial Officer of Fosun International, said, "Looking ahead, Fosun will maintain its business streamlining and resilience building strategy, continue to focus on the development of its core businesses, enhance its industry operations capability and global competitiveness, and achieve high-value growth in return for investors' trust." About Fosun Fosun was founded in 1992. After more than 30 years of development, Fosun has become a global innovation-driven consumer group. Adhering to the mission of creating happier lives for families worldwide, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of one billion families in health, happiness and wealth. In 2007, Fosun International Limited was listed on the main board of the Hong Kong Stock Exchange (stock code: 00656.HK). As of 31 December 2022, Fosun International's total assets amounted to RMB823.1 billion. Fosun International ranks No.589 on the 2022 Forbes Global 2000 List, with a MSCI ESG rating of AA. SOURCE Fosun